Home Other Building Blocks Droloxifene

Droloxifene

CAS No.:
82413-20-5
Catalog Number:
AG00G2A3
Molecular Formula:
C26H29NO2
Molecular Weight:
387.5140
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
Product Description
Catalog Number:
AG00G2A3
Chemical Name:
Droloxifene
CAS Number:
82413-20-5
Molecular Formula:
C26H29NO2
Molecular Weight:
387.5140
MDL Number:
MFCD00865556
IUPAC Name:
3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
InChI:
InChI=1S/C26H29NO2/c1-4-25(20-9-6-5-7-10-20)26(22-11-8-12-23(28)19-22)21-13-15-24(16-14-21)29-18-17-27(2)3/h5-16,19,28H,4,17-18H2,1-3H3/b26-25+
InChI Key:
ZQZFYGIXNQKOAV-OCEACIFDSA-N
SMILES:
CCC(=C(c1cccc(c1)O)c1ccc(cc1)OCCN(C)C)c1ccccc1
EC Number:
428-010-4
UNII:
0M67U6Z98F
Properties
Complexity:
501  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1  
Exact Mass:
387.22g/mol
Formal Charge:
0
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
387.523g/mol
Monoisotopic Mass:
387.22g/mol
Rotatable Bond Count:
8  
Topological Polar Surface Area:
32.7A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
6.8  
Literature
Title Journal
Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and α-fetoprotein. Toxicological sciences : an official journal of the Society of Toxicology 20150201
[Effect of tetrandrine in combination with droloxifen on the expression of NF-kappaB protein in K562 and K562/A02 cell lines]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20080501
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. Journal of molecular graphics & modelling 20061101
[Using protein chips to study mechanism underlying reversion of drug resistance in leukemia cells in tetrandrine alone or in combination with droloxifene]. Zhongguo shi yan xue ye xue za zhi 20051201
Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity. Acta pharmacologica Sinica 20051001
Effects of progesterone and selective oestrogen receptor modulators on chronic allograft nephropathy in rats. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050201
[Effect of tetrandrine combined with Droloxifen on the expression of bcr/abl of K562 at both mRNA and protein levels]. Zhongguo shi yan xue ye xue za zhi 20050201
[Reversal effect of tetrandrine in combination with droloxifene on cell line K562/A02 and its correlation with inducted apoptosis]. Zhongguo shi yan xue ye xue za zhi 20040601
[Study on the relationship between [Ca2+]i and the MDR formation in K562/A02 cells]. Zhongguo shi yan xue ye xue za zhi 20040401
Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. Clinical endocrinology 20040301
[Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin]. Ai zheng = Aizheng = Chinese journal of cancer 20030401
Down-regulation of nitric oxide production by droloxifene and toremifene in human breast cancer cells. Oncology reports 20030101
Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica; the fate of foreign compounds in biological systems 20021001
Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects. Xenobiotica; the fate of foreign compounds in biological systems 20020801
[Antiestrogen therapy in the treatment of breast neoplasms]. Minerva ginecologica 20020601
Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International journal of cancer 20020510
Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast cancer research and treatment 20020501
Toxicity of antiestrogens. The breast journal 20020101
Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women. Medscape women's health 20020101
Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones. Chemical research in toxicology 20011201
Reversal effects of droloxifene on multidrug resistance in adriamycin-resistant K562 cell line. Acta pharmacologica Sinica 20011101
Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. The Journal of clinical endocrinology and metabolism 20010901
Apoptosis induced by droloxifene and C-myc, Bax, Bcl-2 protein expression in corpus luteum of pregnant rats. Acta pharmacologica Sinica 20010401
Effects of droloxifene on apoptosis and Bax, Bcl-2 protein expression of luteal cells in pseudopregnant rats. Acta pharmacologica Sinica 20010201
Oestrogen and progesterone increase the levels of apoptosis induced by the human papillomavirus type 16 E2 and E7 proteins. The Journal of general virology 20010101
Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Women's health issues : official publication of the Jacobs Institute of Women's Health 20010101
[Antiestrogens: mechanism of action and clinical applications]. Salud publica de Mexico 20010101
Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. International journal of cancer 19980911
Properties